Archived
COGR, AAU, and AUTM Submit Joint Association Letter on COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities
The letter, submitted jointly by the Association of American Universities (AAU), the Council on Government Relations (COGR), and AUTM, addresses the U.S. International Trade Commission in relation to Investigation No. 332-596, focusing on COVID-19 diagnostics, therapeutics, and the possible expansion of the TRIPS Agreement waiver. The associations, representing leading American research universiti
Regulatory Review Chart - Pending Regulatory Freeze
The document provides a detailed account of federal rules, regulations, and executive orders that were either revoked, paused, or placed under review following the January 20, 2021, Regulatory Freeze Pending Review Presidential Memorandum, issued at the start of the Biden administration. Major actions included the revocation of prior executive orders such as EO 13950, which addressed race and sex
Joint Association & Institutional Letter to President Trump on Fetal Tissue Research Restrictions and COVID-19
The letter, dated March 25, 2020, is a joint appeal from numerous leading scientific, medical, and patient advocacy organizations to President Donald J. Trump. The signatories urge a reconsideration and immediate lifting of federal restrictions on research involving human fetal tissue, emphasizing the critical role such research plays in developing treatments and vaccines during the COVID-19 pande
COGR Research Regulatory Reform Matrix
The document provides a detailed overview of federal efforts to address regulatory burden and reform policies related to federally funded research, based on statutory requirements from acts such as the 21st Century Cures Act and the American Innovation and Competitiveness Act (AICA). Key reform areas include the establishment of a Research Policy Board, interagency working groups, harmonization of
COGR Common Rule Summary Table
The Common Rule Summary Table outlines significant revisions to federal regulations governing human subjects research. The final rule, effective from January 19, 2018 (with special provisions for cooperative research effective January 20, 2020), distinguishes between non-identified and identifiable biospecimens, treating identifiable biospecimens and private information equivalently and providing
